TY  - JOUR
AU  - Babaei, Masoud
AU  - Jansen, Lina
AU  - Balavarca, Yesilda
AU  - Sjövall, Annika
AU  - Bos, Amanda
AU  - van de Velde, Tony
AU  - Moreau, Michel
AU  - Liberale, Gabriel
AU  - Gonçalves, Ana Filipa
AU  - Bento, Maria José
AU  - Ulrich, Cornelia M
AU  - Schrotz-King, Petra
AU  - Lemmens, Valery
AU  - Glimelius, Bengt
AU  - Brenner, Hermann
TI  - Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes.
JO  - Clinical colorectal cancer and other gastrointestinal malignancies
VL  - 17
IS  - 1
SN  - 1533-0028
CY  - Dallas, Tex.
PB  - Cancer Information Group
M1  - DKFZ-2018-00284
SP  - e129-e142
PY  - 2018
AB  - Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers.Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders.A total of 16,095 rectal cancer patients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95
LB  - PUB:(DE-HGF)16
C6  - pmid:29074354
DO  - DOI:10.1016/j.clcc.2017.09.002
UR  - https://inrepo02.dkfz.de/record/132624
ER  -